CCL22 and esophageal squamous cell carcinoma: In esophageal squamous cell carcinoma (ESCC), stromal TAM-derived CCL22 activates the DGKα/NF-κB pathway, upregulating multiple ATP-binding cassette transporters and reducing intracellular cisplatin accumulation, thereby promoting cisplatin resistance [119].